Show simple item record

dc.contributor.authorPatil, Ketan S.en_US
dc.contributor.authorBasak, Indranilen_US
dc.contributor.authorDalen, Ingvilden_US
dc.contributor.authorHoedt, Esthelleen_US
dc.contributor.authorLange, Johannesen_US
dc.contributor.authorLunde, Kristin Aaseren_US
dc.contributor.authorLiu, Yingen_US
dc.contributor.authorTysnes, Ole-Bjørnen_US
dc.contributor.authorForsgren, Larsen_US
dc.contributor.authorAarsland, Dagen_US
dc.contributor.authorNeubert, Thomas A.en_US
dc.contributor.authorLarsen, Jan Petteren_US
dc.contributor.authorAlves, Guido Werneren_US
dc.contributor.authorMøller, Simon Geiren_US
dc.PublishedPatil KS, Basak I, Dalen I, Hoedt E, Lange J, Lunde K, Liu Y, Tysnes O, Forsgren L, Aarsland D, Neubert TA, Larsen JP, Alves G, Møller SG. Combinatory microRNA serum signatures as classifiers of Parkinson's disease. Parkinsonism & Related Disorders. 2019;64:202-210eng
dc.description.abstractIntroduction: As current clinical diagnostic protocols for Parkinson's disease (PD) may be prone to inaccuracies there is a need to identify and validate molecular biomarkers, such as circulating microRNAs, which will complement current practices and increase diagnostic accuracy. This study identifies, verifies and validates combinatory serum microRNA signatures as diagnostic classifiers of PD across different patient cohorts. Methods: 370 PD (drug naïve) and control serum samples from the Norwegian ParkWest study were used for identification and verification of differential microRNA levels in PD which were validated in a blind study using 64 NY Parkinsonism in UMeå (NYPUM) study serum samples and tested for specificity in 48 Dementia Study of Western Norway (DemWest) study Alzheimer's disease (AD) serum samples using miRNA-microarrays, and quantitative (q) RT-PCR. Proteomic approaches identified potential molecular targets for these microRNAs. Results: Using Affymetrix GeneChip® miRNA 4.0 arrays and qRT-PCR we comprehensively analyzed serum microRNA levels and found that the microRNA (PARKmiR)-combinations, hsa-miR-335-5p/hsa-miR-3613-3p (95% CI, 0.87–0.94), hsa-miR-335-5p/hsa-miR-6865-3p (95% CI, 0.87–0.93), and miR-335-5p/miR-3613-3p/miR-6865-3p (95% CI, 0.87–0.94) show a high degree of discriminatory accuracy (AUC 0.9–1.0). The PARKmiR signatures were validated in an independent PD cohort (AUC ≤ 0.71) and analysis in AD serum samples showed PARKmiR signature specificity to PD. Proteomic analyses showed that the PARKmiRs regulate key PD-associated proteins, including alpha-synuclein and Leucine Rich Repeat Kinase 2. Conclusions: Our study has identified and validated unique miRNA serum signatures that represent PD classifiers, which may complement and increase the accuracy of current diagnostic protocols.en_US
dc.rightsAttribution-NonCommercial-NoDerivs CC BY-NC-NDeng
dc.titleCombinatory microRNA serum signatures as classifiers of Parkinson's diseaseen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2019 Elsevier
dc.source.journalParkinsonism & Related Disorders

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs CC BY-NC-ND
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs CC BY-NC-ND